Hanyu Medical Completes Nearly RMB 500 Million Series D+ Financing to Advance Innovative Structural Heart Disease Devices

VCBeat (WeChat ID: vcbeat) learned at the earliest opportunity that,On March 15, 2021, Shanghai Hanyu Medical Technology Co., Ltd. officially announced the completion of its Series D+ financing round, totaling nearly RMB 500 million.; This round of financing introduced YF Capital as the lead investor, along with investors including Jiangsu Ruihua, Octagon Capital, E Fund, and Lingdao Capital. Existing shareholder Honghui Capital continued its investment. Bairong Capital served as the exclusive financial advisor for this round of financing.

Hanyu Medical, as a leading platform-based innovative medical device R&D and industrialization company in China, is dedicated to the R&D and commercialization of innovative medical devices for structural heart disease, and is also a leading enterprise in China for the R&D, production, and sales of interventional cardiac valve medical devices;

ValveClamp, a mitral valve interventional repair device independently developed by the company, holds global invention patents and is used for minimally invasive interventional treatment of mitral regurgitation. ValveClamp completed exploratory human clinical trials with 12 cases in October 2018 and officially launched pre-market clinical trials in February 2019. It is the first domestically developed minimally invasive interventional device for mitral valve treatment to enter pre-market clinical trials in China, and is expected to become the first domestically produced mitral valve interventional repair device marketed in China following Abbott.

Hongyu Medical, a subsidiary of Hanyu Medical, serves as the company’s platform for the research and development and commercialization of veterinary medical devices. It is the first company globally to develop interventional medical devices for mitral regurgitation in pet dogs. Leveraging the company’s extensive experience in clinical research and development, Hongyu Medical has developed a portfolio of products targeting the treatment of structural heart disease in pets. The company has successively established collaborations with veterinary medical teams in multiple countries, including the United States, Italy, Japan, Spain, the United Kingdom, and Israel.

Dr. Huang Xiao, Executive Director of YF CapitalIt stated: “Hanyu Medical is a paradigm of integrating medicine and engineering, collaborating deeply with top-tier medical teams in China while possessing strong in-house R&D capabilities. It is poised to successfully develop the first domestically produced mitral valve repair product. Compared to the aortic valve sector, the mitral valve field has a larger potential patient population and greater unmet clinical needs. Hanyu Medical’s core product, ValveClamp, is expected to become the first innovative medical device for mitral valve repair launched in China, thereby benefiting a broader patient population. Based on this investment, YF Capital will assist Hanyu Medical in establishing deep collaboration within the Yunfeng ecosystem, hoping that Hanyu Medical will develop more innovative medical devices in the field of structural heart disease to benefit patients.”

Dai Yufeng, Chairman of Hanyu Medicalstated: “We are grateful for the continued recognition of Hanyu Medical by the investors in this round. Guided by its mission to ‘safeguard lives and benefit the world,’ Hanyu Medical is continuously developing minimally invasive interventional medical devices covering various heart valve diseases and other structural heart disease products, striving to build a comprehensive platform for structural heart disease solutions.”